Prognostic significance of early lymphocyte recovery in pediatric osteosarcoma

Pediatric Blood and Cancer

Volumn 55, Issue 6, 2010, Pages 1096-1102

  Moore, Colin ^a   Eslin, Don ^b   Levy, Alejandro ^b   Roberson, Jessica ^b   Giusti, Vincent ^b   Sutphin, Robert ^b  

^a ORLANDO HEALTH   (United States)

^b ARNOLD PALMER HOSPITAL FOR CHILDREN   (United States)

Author keywords

Absolute lymphocyte count; Osteosarcoma; Prognostic factor

Indexed keywords

ADOLESCENT; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RELAPSE; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; COHORT ANALYSIS; EARLY LYMPHOCYTE RECOVERY; FEMALE; HUMAN; LATE LYMPHOCYTE RECOVERY; LYMPHOCYTE COUNT; MALE; METASTASIS; ONCOLOGICAL PARAMETERS; OSTEOSARCOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SCHOOL CHILD; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; OSTEOSARCOMA; PROGNOSIS; RECOVERY OF FUNCTION; RISK FACTORS; SURVIVAL RATE; YOUNG ADULT;

EID: 77954695842     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22673     Document Type: Article

References (39)

1. Singh GK, Yu SM. US childhood mortality, 1950 through 1993: Trends and socioeconomic differentials. Am J Public Health 1996; 86: 505-512.
2. Mirabello L, Troisi RJ, Savage SA. International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer 2009; 125: 229-234.
3. Meyers PA, Heller G, Healey JH, et al. Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J Clin Oncol 1993; 11: 449-453.
4. Meyers PA, Schwartz CL, Krailo MD, et al. Osteosarcoma: The addition of muramyl tripeptide to chemotherapy improves overall survival-A report from the Children's Oncology Group. J Clin Oncol 2008; 26: 633-638.
5. Damron TA, Ward WG, Stewart A. Osteosarcoma, chondrosarcoma, and Ewing's sarcoma: National Cancer Data Base Report. Clin Orthop Relat Res 2007; 459: 40-47.
6. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1, 702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002; 20: 776-790.
7. Bacci G, Ferrari S, Bertoni F, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: An updated report. J Clin Oncol 2000; 18: 4016-4027.
8. Bielack S, Carrle D, Casali PG. Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20: 137-139.
9. Chou AJ, Geller DS, Gorlick R. Therapy for osteosarcoma: Where do we go from here? Paediatr Drugs 2008; 10: 315-327.
10. Bramer JA, van Linge JH, Grimer RJ, et al. Prognostic factors in localized extremity osteosarcoma: A systematic review. Eur J Surg Oncol 2009; 35: 1030-1036.
11. Pakos EE, Nearchou AD, Grimer RJ, et al. Prognostic factors and outcomes for osteosarcoma: An international collaboration. Eur J Cancer 2009; 45: 2367-2375.
12. Zhou H, Randall RL, Brothman AR, et al. Her-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification. J Pediatr Hematol Oncol 2003; 25: 27-32.
13. Meyers PA, Heller G, Healey J, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: The Memorial Sloan-Kettering experience. J Clin Oncol 1992; 10: 5-15.
14. Provisor AJ, Ettinger LJ, Nachman JB, et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: A report from the Children's Cancer Group. J Clin Oncol 1997; 15: 76-84.
15. Bacci G, Forni C, Ferrari S, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremity: Intensification of preoperative treatment does not increase the rate of good histologic response to the primary tumor or improve the final outcome. J Pediatr Hematol Oncol 2003; 25: 845-853.
16. De Angulo G, Yuen C, Palla SL, et al. Absolute lymphocyte count is a novel prognostic indicator in ALL and AML: Implications for risk stratification and future studies. Cancer 2008; 112: 407-415.
17. De Angulo G, Hernandez M, Morales-Arias J, et al. Early lymphocyte recovery as a prognostic indicator for high-risk Ewing sarcoma. J Pediatr Hematol Oncol 2007; 29: 48-52.
18. Porrata LF, Gertz MA, Inwards DJ, et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood 2001; 98: 579-585.
19. Porrata LF, Ingle JN, Litzow MR, et al. Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. Bone Marrow Transplant 2001; 28: 865-871.
20. Porrata LF, Litzow MR, Tefferi A, et al. Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute myelogenous leukemia. Leukemia 2002; 16: 1311-1318.
21. DuBois SG, Elterman K, Grier HE. Early lymphocyte recovery in Ewing sarcoma. J Pediatr Hematol Oncol 2007; 29: 351-352.
22. Bacci G, Ferrari S, Bertoni F, et al. Histologic response of high-grade nonmetastatic osteosarcoma of the extremity to chemotherapy. Clin Orthop Relat Res 2001; 386: 186-196.
23. Whelan JWS, Uscinska B, et al. Localised extremity osteosarcoma: Mature survival data from two European Osteosarcoma Intergroup randomized clinical trials. Proc Am Soc Clin 2000; 19: 1281a.
24. Ray-Coquard I, Cropet C, Van Glabbeke M, et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res 2009; 69: 5383-5391.
25. Castriconi R, Dondero A, Cilli M, et al. Human NK cell infusions prolong survival of metastatic human neuroblastoma-bearing NOD/scid mice. Cancer Immunol Immunother 2007; 56: 1733-1742.
26. Brentjens RJ, Santos E, Nikhamin Y, et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res 2007; 13: 5426-5435.
27. Suck G. Novel approaches using natural killer cells in cancer therapy. Semin Cancer Biol 2006; 16: 412-418.
28. Wang G, Tschoi M, Spolski R, et al. In vivo antitumor activity of interleukin 21 mediated by natural killer cells. Cancer Res 2003; 63: 9016-9022.
29. Fuchs N, Bielack SS, Epler D, et al. Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol 1998; 9: 893-899.
30. Lee JW, Kim H, Kang HJ, et al. Clinical characteristics and treatment results of pediatric osteosarcoma: The role of high dose chemotherapy with autologous stem cell transplantation. Cancer Res Treat 2008; 40: 172-177.
31. Mori K, Redini F, Gouin F, et al. Osteosarcoma: Current status of immunotherapy and future trends (Review). Oncol Rep 2006; 15: 693-700.
32. Anderson P, Kopp L, Anderson N, et al. Novel bone cancer drugs: Investigational agents and control paradigms for primary bone sarcomas (Ewing's sarcoma and osteosarcoma). Expert Opin Investig Drugs 2008; 17: 1703-1715.
33. Loeb DM, Garrett-Mayer E, Hobbs RF, et al. Dose-finding study of 153Sm-EDTMP in patients with poor-prognosis osteosarcoma. Cancer 2009; 115: 2514-2522.
34. Liu LL, Smith MJ, Sun BS, et al. Combined IFN-gamma-endostatin gene therapy and radiotherapy attenuates primary breast tumor growth and lung metastases via enhanced CTL and NK cell activation and attenuated tumor angiogenesis in a murine model. Ann Surg Oncol 2009; 16: 1403-1411.
35. Moghrabi A, Levy DE, Asselin B, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood 2007; 109: 896-904.
36. Borowitz MJ, Devidas M, Hunger SP, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: A Children's Oncology Group study. Blood 2008; 111: 5477-5485.
37. Flohr T, Schrauder A, Cazzaniga G, et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia 2008; 22: 771-782.
38. Vrooman LM, Silverman LB. Childhood acute lymphoblastic leukemia: Update on prognostic factors. Curr Opin Pediatr 2009; 21: 1-8.
39. Dantonello TM, Int-Veen C, Harms D, et al. Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults. J Clin Oncol 2009; 27: 1446-1455.